Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy

Nature Medicine

Volumn 19, Issue 4, 2013, Pages 488-493

  Rowe, Isaline ^a   Chiaravalli, Marco ^a   Mannella, Valeria ^b   Ulisse, Valeria ^a   Quilici, Giacomo ^b   Pema, Monika ^a   Song, Xuewen W ^c   Xu, Hangxue ^d,e   Mari, Silvia ^b,e,f   Qian, Feng ^d,e   Pei, York ^c   Musco, Giovanna ^b   Boletta, Alessandra ^a  

^a DULBECCO TELETHON INSTITUTE   (Italy)

^b Biomolecular NMR Laboratory   (Italy)

^c UNIVERSITY OF TORONTO   (Canada)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f Research 4 Rent   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; DEOXYGLUCOSE; LIVER KINASE B1 AMP ACTIVATED PROTEIN KINASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; AMP ACTIVATED PROTEIN KINASE KINASE; AMP-ACTIVATED PROTEIN KINASE KINASE; GLUCOSE; POLYCYSTIC KIDNEY DISEASE 1 PROTEIN; POLYCYSTIN; PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE; GENE MUTATION; GLUCOSE METABOLISM; GLYCOLYSIS; KIDNEY MASS; KIDNEY POLYCYSTIC DISEASE; MALE; METABOLIC RATE; MOUSE; NONHUMAN; POLYCYSTIN 1 GENE; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; KIDNEY; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

MUS;

ANIMALS; DEOXYGLUCOSE; DISEASE MODELS, ANIMAL; GLUCOSE; GLYCOLYSIS; HUMANS; KIDNEY; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POLYCYSTIC KIDNEY DISEASES; PROTEIN KINASES; TRPP CATION CHANNELS;

MLCS; MLOWN;

EID: 84878434156     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3092     Document Type: Article

References (33)

1. Torres, V.E., Harris, P.C. & Pirson, Y. Autosomal dominant polycystic kidney disease. Lancet 369, 1287-1301 (2007).
2. Harris, P.C. & Torres, V.E. Polycystic kidney disease. Annu. Rev. Med. 60, 321-337 (2009).
3. Takiar, V. & Caplan, M.J. Polycystic kidney disease: pathogenesis and potential therapies. Biochim. Biophys. Acta 1812, 1337-1343 (2011).
4. Grantham, J.J., Geiser, J.L. & Evan, A.P. Cyst formation and growth in autosomal dominant polycystic kidney disease. Kidney Int. 31, 1145-1152 (1987).
5. Torres, V.E. et al. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin. J. Am. Soc. Nephrol. 5, 1312-1329 (2010).
6. Distefano, G. et al. Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol. Cell Biol. 29, 2359-2371 (2009).
7. Forseth, R.R. & Schroeder, F.C. NMR-spectroscopic analysis of mixtures: from structure to function. Curr. Opin. Chem. Biol. 15, 38-47 (2011).
8. Garcia-Manteiga, J.M. et al. Metabolomics of B to plasma cell differentiation. J. Proteome Res. 10, 4165-4176 (2011).
9. Vander Heiden, M.G., Cantley, L.C. & Thompson, C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009).
10. Düvel, K. et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39, 171-183 (2010).
11. Yecies, J.L. & Manning, B.D. Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res. 71, 2815-2820 (2011).
12. Chiaradonna, F. et al. From cancer metabolism to new biomarkers and drug targets. Biotechnol. Adv. 30, 30-51 (2012).
13. Woo, D. Apoptosis and loss of renal tissue in polycystic kidney diseases. N. Engl. J. Med. 333, 18-25 (1995).
14. Merrick, D. et al. The γ-secretase cleavage product of polycystin-1 regulates TCF and CHOP-mediated transcriptional activation through a p300-dependent mechanism. Dev. Cell 22, 197-210 (2012).
15. Choo, A.Y. et al. Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol. Cell 38, 487-499 (2010).
16. Zheng, B. et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol. Cell 33, 237-247 (2009).
17. Shibazaki, S. et al. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum. Mol. Genet. 17, 1505-1516 (2008).
18. Song, X. et al. Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Hum. Mol. Genet. 18, 2328-2343 (2009).
19. Foxall, P.J. et al. High resolution proton magnetic resonance spectroscopy of cyst fluids from patients with polycystic kidney disease. Biochim. Biophys. Acta 1138, 305-314 (1992).
20. Yu, S. et al. Essential role of cleavage of polycystin-1 at G protein-coupled receptor proteolytic site for kidney tubular structure. Proc. Natl. Acad. Sci. USA 104, 18688-18693 (2007).
21. Csibi, A. & Blenis, J. Appetite for destruction: the inhibition of glycolysis as a therapy for tuberous sclerosis complex-related tumors. BMC Biol. 9, 69 (2011).
22. Shillingford, J.M. et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl. Acad. Sci. USA 103, 5466-5471 (2006).
23. Shillingford, J.M., Piontek, K.B., Germino, G.G. & Weimbs, T. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J. Am. Soc. Nephrol. 21, 489-497 (2010).
24. Serra, A.L. et al. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrol. 8, 13 (2007).
25. Walz, G. et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 830-840 (2010).
26. Serra, A.L. et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 820-829 (2010).
27. McCarty, M.F., Barroso-Aranda, J. & Contreras, F. Activation of AMP-activated kinase as a strategy for managing autosomal dominant polycystic kidney disease. Med. Hypotheses 73, 1008-1010 (2009).
28. Takiar, V. et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc. Natl. Acad. Sci. USA 108, 2462-2467 (2011).
29. Cheong, J.H. et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol. Cancer Ther. 10, 2350-2362 (2011).
30. Bastos, A.P. et al. Pkd1 haploinsufficiency increases renal damage and induces microcyst formation following ischemia/reperfusion. J. Am. Soc. Nephrol. 20, 2389-2402 (2009).
31. Wodarczyk, C. et al. Nephrocystin-1 forms a complex with polycystin-1 via a polyproline motif/SH3 domain interaction and regulates the apoptotic response in mammals. PLoS ONE 5, e12719 (2010).
32. Wodarczyk, C. et al. A novel mouse model reveals that polycystin-1 deficiency in ependyma and choroid plexus results in dysfunctional cilia and hydrocephalus. PLoS ONE 4, e7137 (2009).
33. Shao, X., Somlo, S. & Igarashi, P. Epithelial-specific Cre/lox recombination in the developing kidney and genitourinary tract. J. Am. Soc. Nephrol. 13, 1837-1846 (2002).